Patent Covering The Use And Pharmaceutical Composition Of Isofol Medical AB’s Lead Drug Candidate, Modufolin, Allowed By United States Patent And Trademark Office
Isofol Medical AB today announced that the United States Patent and Trademark Office has allowed Isofol’s patentNo. 12/805,287, covering the use and pharmaceutical composition of [6R]-methylene-tetrahydrofolate (Modufolin®), to reduce toxicity resulting from multi-targeting antifolate chemotherapy.
Isofol provided evidence demonstrating the clear superiority of Modufolin® over folic acid in reducing pemetrexed toxicity. “I am very pleased that the superiority of Modufolin® has been accepted by the United States Patent and Trademark Office and that this patent has been allowed. It will provide Modufolin® with long-term market exclusivity in this application” said Anders Rabbe, CEO of Isofol Medical.
Modufolin® is currently being evaluated in two Phase I/II studies, in colorectal cancer and in osteosarcoma.
About Modufolin®
Modufolin® (chemical name [6R]-5,10-methylenetetrahydrofolate), is a novel folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of all clinically used folate-based drugs today including leucovorin and levoleucovorin and therefore does not require metabolic activation. This makes Modufolin® suitable for all patients irrespective of their capacity to activate folates and it is currently being evaluated in clinical Phase 1/II studies.
About Isofol Medical AB
Isofol Medical is a clinical stage pharmaceutical company developing novel products for unmet needs within oncology. Isofol’s lead clinical candidate is Modufolin®. Isofol Medical collaborates closely with its strategic R&D partner Merck Millipore, the world’s leading manufacturer of reduced folates including leucovorin and levoleucovorin.
For more information please visit www.isofolmedical.se
For more information, please contact:
Anders Rabbe, CEO, Isofol Medical AB
E¬mail: anders.rabbe@isofolmedical.com Phone: +46 (0)707 646 500
Modufolin® is a registered Trademark of Merck KGaA, Darmstadt, Germany.
Isofol Medical is based on 30 years of medical research which has resulted in the novel folate-based pharmaceutical product Modufolin®. Modufolin® is anticipated to increase the efficacy and reduce the side effects of cytotoxic pharmaceuticals. Isofol works closely with its strategic Swiss R&D partner Merck & Cie, the world’s leading manufacturer of reduced folates. In parallel to the drug development, Isofol Medical is performing diagnostic research to personalize and optimize the use of folate-based therapies for cancer treatment.
Help employers find you! Check out all the jobs and post your resume.
Isofol provided evidence demonstrating the clear superiority of Modufolin® over folic acid in reducing pemetrexed toxicity. “I am very pleased that the superiority of Modufolin® has been accepted by the United States Patent and Trademark Office and that this patent has been allowed. It will provide Modufolin® with long-term market exclusivity in this application” said Anders Rabbe, CEO of Isofol Medical.
Modufolin® is currently being evaluated in two Phase I/II studies, in colorectal cancer and in osteosarcoma.
About Modufolin®
Modufolin® (chemical name [6R]-5,10-methylenetetrahydrofolate), is a novel folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of all clinically used folate-based drugs today including leucovorin and levoleucovorin and therefore does not require metabolic activation. This makes Modufolin® suitable for all patients irrespective of their capacity to activate folates and it is currently being evaluated in clinical Phase 1/II studies.
About Isofol Medical AB
Isofol Medical is a clinical stage pharmaceutical company developing novel products for unmet needs within oncology. Isofol’s lead clinical candidate is Modufolin®. Isofol Medical collaborates closely with its strategic R&D partner Merck Millipore, the world’s leading manufacturer of reduced folates including leucovorin and levoleucovorin.
For more information please visit www.isofolmedical.se
For more information, please contact:
Anders Rabbe, CEO, Isofol Medical AB
E¬mail: anders.rabbe@isofolmedical.com Phone: +46 (0)707 646 500
Modufolin® is a registered Trademark of Merck KGaA, Darmstadt, Germany.
Isofol Medical is based on 30 years of medical research which has resulted in the novel folate-based pharmaceutical product Modufolin®. Modufolin® is anticipated to increase the efficacy and reduce the side effects of cytotoxic pharmaceuticals. Isofol works closely with its strategic Swiss R&D partner Merck & Cie, the world’s leading manufacturer of reduced folates. In parallel to the drug development, Isofol Medical is performing diagnostic research to personalize and optimize the use of folate-based therapies for cancer treatment.
Help employers find you! Check out all the jobs and post your resume.